MN-ENTRUST-DATACARD
11.2.2020 15:02:10 CET | Business Wire | Press release
Entrust Datacard , a leading provider of trusted identity and secure issuance technology solutions, today announced two new high-assurance offerings for the company’s unified authentication management platform: Passwordless Single Sign On (SSO) Authentication to improve workforce security and productivity, and Identity Proofing with fully digital identity verification for accelerated customer acquisition and onboarding.
As digital transformation, cloud deployments and mobile initiatives make communication, data storage and remote workstyles dramatically simpler, employees and customers around the world expect security features to follow suit, without compromising user experiences. The latest Entrust Datacard authentication solutions both increase high-assurance security and simplify user experiences.
Entrust Datacard’s Passwordless SSO Authentication solution turns employee smartphones into biometrics-protected virtual smart cards that allow instant proximity-based login to both workstations and applications. The solution creates a frictionless authentication experience, eliminating passwords and putting an end to the risk of bad actors stealing user credentials and compromising critical information.
Taking passwordless login to an SSO experience removes the friction of individual registrations and logins for each device, allowing employees to work across devices and applications – cloud-based and on-premises. The solution improves workforce productivity by enabling employees to securely conduct their work activities – email signing, file encryption, document signing, and more – from their office or remote location without the need to upgrade their hardware or operating system.
Entrust Datacard’s new Identity Proofing solution lets banks, hospitals, government agencies and other customer and citizen-facing organizations offer customers a simple, seamless onboarding experience, either inside or outside physical locations. With Identity Proofing, customers use their smartphones or a kiosk to capture their images and scan government-issued identity documents – such as a driver’s license, passport or national ID card – for fast, AI-based authentication and verification.
Once authenticated and verified, the user can complete their account application securely. This minimizes abandoned account applications, cuts onboarding time from multiple days to minutes and has the potential to reduce an organization’s onboarding costs from hundreds of dollars per account to single digits. The fully digital Identity Proofing solution supports compliance with regional regulations, such as Know Your Customer (KYC) and Anti-Money Laundering (AML) in the United States, and PSD2 in Europe.
“Digital transformation is driving the demand for authentication that is both incredibly easy and highly secure – features once thought incompatible,” said James LaPalme, VP and GM of Authentication at Entrust Datacard. “By delivering passwordless SSO authentication, enterprises can eliminate passwords and transform the employee experience, while increasing privacy and data security. Similarly, our Identity Proofing solution creates a truly digital customer onboarding experience, streamlining and automating what has until now been a costly, manual and less-secure process behind the scenes.”
To learn more about the Entrust Datacard Passwordless SSO Authentication and Identity Proofing solutions visit RSA Conference booth #S-2139 from February 24-28 at the Moscone Center in San Francisco or head to https://www.entrustdatacard.com/products/categories/authentication .
About Entrust Datacard Corporation
Consumers, citizens and employees increasingly expect anywhere-anytime experiences — whether they are making purchases, crossing borders, accessing e-gov services or logging onto corporate networks. Entrust Datacard offers the trusted identity and secure issuance technologies that make those experiences reliable and secure. Solutions range from the physical world of financial cards, passports and ID cards to the digital realm of authentication, certificates, hardware security modules and secure communications. With more than 2,800 Entrust Datacard colleagues around the world, and a network of strong global partners, the company serves customers in 150 countries worldwide. For more information, visit www.entrustdatacard.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005372/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom